You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness II1 Apr 2012280 MATCHING TUMOR RISK WITH AGGRESSIVENESS OF TREATMENT IN MEN WITH SEVERE COMORBIDITY AND NON-METASTATIC PROSTATE CANCER Timothy J. Daskivich, Karim Chamie, Atreya Dash, Sheldon Greenfield, and Mark S. Litwin Timothy J. DaskivichTimothy J. Daskivich Los Angeles, CA More articles by this author , Karim ChamieKarim Chamie Los Angeles, CA More articles by this author , Atreya DashAtreya Dash Irvine, CA More articles by this author , Sheldon GreenfieldSheldon Greenfield Irvine, CA More articles by this author , and Mark S. LitwinMark S. Litwin Los Angeles, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.338AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Men with multiple comorbidities are often overtreated for low-risk prostate cancer, given high likelihood of other-cause mortality and low likelihood of prostate cancer mortality. However, it is unclear whether such men are undertreated for high-risk disease, which has an appreciable short-term risk of prostate cancer mortality. We aimed to characterize the impact of comorbidity on treatment choice in men with non-metastatic prostate cancer and differing tumor risks. METHODS We sampled 1,482 men with newly diagnosed, non-metastatic prostate cancer at two Southern California VA Hospitals between 1998 and 2004. We first stratified our population by D’Amico tumor risk. We then used a multivariate probit model to determine probabilities and relative risks of aggressive treatment (surgery or radiation therapy) among men with differing Charlson comorbidity index scores within each tumor risk stratum. We then conducted Cox proportional hazards analyses and calculated 8-year non-prostate cancer mortality rates for each tumor risk/comorbidity pair. RESULTS Our sample comprised 516 men (36%) with low-risk, 475 men (33%) with intermediate-risk, and 432 men (30%) with high-risk prostate cancer. Prostate cancer mortality was 0.4%, 3.0%, and 8.0% for men with low-, intermediate-, and high-risk disease, respectively. Men with high-risk disease had a lower probability of aggressive treatment than other risk strata, irrespective of comorbidity score (see Table). Among men with Charlson scores 3+, probabilities of aggressive treatment did not increase with higher tumor risk (0.48, 0.61, 0.49 for low-, intermediate-, and high-risk disease, respectively). The risk of non-prostate cancer mortality increased with stepwise increases in Charlson score in all tumor risk strata. Probabilities and Relative Risks of Aggressive Treatment by Charlson Score and D’Amico Tumor Risk, with Corresponding Risks of Non-Prostate Cancer Mortality Tumor Risk Charlson Score Multivariate Probability of Aggressive Treatment Multivariate Relative Risk of Aggressive Treatment Hazard Ratio for Non-Prostate Cancer Mortality 8-year Non-Prostate Cancer Mortality Rate Low 0 0.69(0.64-0.74) – – 9.1% Low 1 0.65(0.58-0.72) 0.95(0.84-1.06) 3.59(2.05-6.30) 29.2% Low 2 0.60(0.51-0.70) 0.88(0.74-1.02) 4.00(2.24-7.17) 32.4% Low 3+ 0.48(0.37-0.60) 0.70(0.52-0.86) 6.17(3.44-11.06) 44.7% Intermediate 0 0.69(0.64-0.77) – – 17.8% Intermediate 1 0.76(0.70-0.83) 1.11(0.99-1.25) 2.00(1.24-3.25) 30.3% Intermediate 2 0.77(0.68-0.85) 1.11(0.94-1.26) 2.52(1.46-4.36) 38.1% Intermediate 3+ 0.61(0.48-0.76) 0.89(0.67-1.10) 10.53(6.17-17.96) 85.0% High 0 0.59(0.57-0.68) – – 19.9% High 1 0.57(0.53-0.66) 0.98(0.81-1.21) 1.66(1.05-2.62) 30.8% High 2 0.54(0.48-0.67) 0.93(0.71-1.18) 4.76(2.95-7.66) 63.6% High 3+ 0.49(0.41-0.63) 0.83(0.61-1.09) 7.49(4.77-11.75) 79.9% CONCLUSIONS Aggressiveness of treatment is poorly matched with tumor risk in men with severe comorbidity. Men with multiple major comorbidities should consider conservative management for low- and intermediate-risk disease and aggressive treatment for high-risk disease. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e114 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Timothy J. Daskivich Los Angeles, CA More articles by this author Karim Chamie Los Angeles, CA More articles by this author Atreya Dash Irvine, CA More articles by this author Sheldon Greenfield Irvine, CA More articles by this author Mark S. Litwin Los Angeles, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...